DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

161 reported adverse events

Drug classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE:

# Side effect Count
0 DEATH 17
1 NAUSEA 16
2 WEIGHT INCREASED 16
3 PAIN 13
4 ANXIETY 10
5 DIARRHOEA 10
6 EMOTIONAL DISTRESS 10
7 DEPRESSION 9
8 PATHOGEN RESISTANCE 9
9 PRODUCT DOSE OMISSION ISSUE 9
See all common reactions for DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ADRENAL ANDROGEN EXCESS 5 0.8333
1 CHOANAL STENOSIS 4 0.1667
2 BLOOD HIV RNA BELOW ASSAY LIMIT 2 0.1333
3 RENAL SCAN ABNORMAL 1 0.0161
4 ALCOHOL USE DISORDER 1 0.0100
5 ACETABULUM FRACTURE 2 0.0063
6 PROSTATIC ADENOMA 1 0.0063
7 ANDROGENETIC ALOPECIA 1 0.0046
8 HEPATITIS B CORE ANTIBODY POSITIVE 1 0.0034
9 BONE DEMINERALISATION 3 0.0032
See all enriched reactions for DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE